Comparing pOrtable MRI and TRUS-Fusion Prostate Biopsy to Assess aCcuracy of Prostate Cancer Detection

Prostate Cancer Clinical Trial

— IP10-COMPACT  

Official title:

Comparing pOrtable MRI and TRUS-Fusion Prostate Biopsy to Assess aCcuracy of Prostate Cancer Detection

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06453785
• Other study ID #: 22CX7739
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 2025
• Est. completion date: July 2027

Study information

• Verified date: June 2024
• Source: Imperial College London
• Contact: Taimur Shah, Dr
• Phone: 020 3311 6611
• Email: t.shah[@]imperial.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Currently, patients suspected of having prostate cancer undergo an MRI followed by targeted biopsies of any suspicious lesions under trans-rectal ultrasound (TRUS) guidance. This pathway is labour, time, and cost-intensive. Additionally, TRUS-MRI-Fusion devices are needed, which overlay the MRI scan onto the TRUS used for biopsies. This can lead to targeting errors due to mismatched images. Although biopsies can be performed in the MRI scanner to reduce these errors, it requires a significant amount of time within an expensive MRI scanner in the radiology department, along with special MRI-compatible equipment. Portable MRI technology has the potential to reduce these errors and streamline the diagnostic pathway to one visit. The Promaxo portable MRI is an FDA-cleared MRI device for MR-guided procedures. It uses a novel "truly" open MRI with an unobstructed field of view and a central aperture for robotic-guided intervention and has a limited footprint, allowing it to be placed in a standard operating theatre or large clinic room. The strength of the magnet is also low enough that special precautions and equipment are not needed to take biopsies. The intention is to conduct a study that answers the following research question: How does the accuracy of targeted biopsies of the prostate performed under the guidance of a portable MRI scanner compare to TRUS-MRI-fusion biopsies? Design: A single-arm, single-center IDEAL stage 2a study (n=85 patients) of patients undergoing prostate biopsy for suspected prostate cancer, where each patient would undergo both a portable MRI-registered biopsy and a TRUS-image-fusion biopsy. To reduce the risk of bias between the two modalities, the order of the modality will be randomized 1:1. There will be no blinding of the surgeon. The primary outcome will be the technical feasibility of performing portable MRI and portable MRI-targeted biopsies and estimates on cancer detection.

Description:

Design: A single arm, singe centre study of 85 patients who have been selected to undergo prostate biopsy for suspected prostate cancer. Each patient would undergo both a portable MRI registered biopsy and the local standard ultrasound fusion biopsy. To reduce the risk of bias between the two types of biopsy the sequence will be randomised 1:1. There will be no blinding of the surgeon. Patient Journey: Patients eligible for the study will have already undergone a standard of care prostate MRI and offered a biopsy for any suspicious lesions seen. Eligible Patients will initially be contacted by a member of the study team and given written information on the study, After a period of time for the patient to review the information the patient will be contacted to give consent which can either be performed remotely or face-to-face. After consent they will be asked to fill in questionnaires for baseline genito-urinary and bowel function using validated questionnaires and overall health status; this will be online or via paper copies. The questionnaires will consist of the HADS score questionnaire, EPIC (urinary, erectile, bowel) questionnaires and EuroQoL [EQ-5D-5L]. Patients who have consented to the study will then undergo a combined biopsy procedure either under local anaesthetic or if the patient wishes under sedation or general anaesthetic. The current biopsy standard operating procedure (SOP) requires that 6 targeted cores per-lesion are taken along with 10-12 systematic cores of the remaining prostate. To ensure patient do not have cores taken in excess of the local SOP each enrolled patient will undergo transperineal prostate biopsy under local anaesthetic or sedation/general anaesthetic with a total of 6-targeted cores taken per lesion (three using each biopsy modality, ultrasound fusion or Portable MRI). All suspicious lesions will biopsied. The patient will then be seen again in either in clinic (remote or face to face) to be given their biopsy results 2-12 weeks after the biopsy. The time point for this appointment will depend on the processing time of the biopsies by the pathology department as per the local standard of care clinical pathway. At this visit patients will be asked again to fill in questionnaires for baseline genito-urinary and bowel function using validated questionnaires and overall health status; this will be online or via paper copies. The questionnaires will consist of the HADS score questionnaire, EPIC (urinary, erectile, bowel) questionnaires and EuroQoL [EQ-5D-5L]. All the above visits mirror the local standard of care clinical pathway and except for the consent visit which could take place on the same day of the biopsy if the patient wishes there will be no additional burden of visits upon the patient. There will be some optional consent points: First, patients will also be asked to give optional consent for identifiable data to be linked with the national databases (ONS and HES database). Subsequent funding will be applied for from academic and charity funders to allow to carry out the linkage work. The identifiable fields (NHS number) required for linkage will be encrypted using a one-way encryption algorithm. Patients will be asked if they are happy to give consent for their health status to be followed up over time. This will be done by linking their name and NHS number with records held by the NHS and maintained by the NHS Information Centre and NHS Central Register or any applicable NHS information system. This will allow to track what happens after the study finishes and observe if anyone gets cancer in future and about the type of cancer and treatment they have had. Patients will be asked whether or not they give permission to be contacted by member of the study research team within 10 years of signing their health status (including details of any other tests and treatment they have had since the study) and quality of life. If the patient decides to take part a member of the study research team may send this request to the patient's home address. The intention is to link individual trial informationto national databases on cancer diagnosis, GP databases on healthcare and medication use and finally death registry to see if any of the men died from prostate cancer. As prostate cancer is often a slow-growing disease which may not progress for many years, patients will also be asked if they are happy to keep personal data stored or accessed for 10 years on the NHSCR (National Health Service Care Register). Second, in order to get an area based estimate of deprivation, the participants' partial postcodes will be converted into an Index of Multiple Deprivation (IMD) score. The IMD is the established index of deprivation for England and Wales and has been adopted widely in studies across local and national government. Partial postcodes will be stored in the study database, only IMD rank, which is based on detailed ward-level index of deprivation based on severe separate domains.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 85
• Est. completion date: July 2027
• Est. primary completion date: April 2027
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or above (no upper limit)
• Raised age specific PSA
• LIKERT/PIRADS 3 or above lesion on prostate mpMRI who have been advised to undergo a prostate biopsy.

Exclusion Criteria:

• Patients who are unable to undergo a diagnostic standard of care MRI due to metallic implants, foreign body or devices.
• Patients with a Cardiac pacemaker or Implantable cardioverter-defibrillator (ICD).
• Contraindication to performing a biopsy guided by a transrectal ultrasound probe
• Unable to give informed consent to the study

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• Promaxo portable MRI
The Promaxo portable MRI is an FDA cleared MRI device for MR-guided procedures. It uses a novel "truly" open MRI with an unobstructed field of view and central aperture for robotic guided intervention and has a limited footprint allowing it to be places in a standard operating theatre or large clinic room. The strength of magnet is also low enough that special precautions and equipment are not to take biopsies.

Locations

Country	Name	City	State
United Kingdom	Imperial College London	London

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Clinicical Significance of Cancer Detected	The proportion of patients with biopsy cores that yield cancer-positive results and the concordance between MRI-guided biopsy results and histopathological findings.	2 years
Primary	Technical feasibility of performing portable MRI and portable MRI targeted biopsies.	Percentage of biopsy completed	2 years
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	The Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 is a standardized system for grading the severity of adverse events (AEs) in clinical trials and medical practice. In CTCAE v4.0, adverse events are graded on a scale from Grade 1 to Grade 5, with each grade indicating increasing severity: Grade 1: Mild AE Grade 2: Moderate AE Grade 3: Severe or medically significant but not immediately life-threatening AE Grade 4: Life-threatening consequences AE Grade 5: Death related to AE	2 years
Secondary	Patient reported outcome measures (PROMS / HADS-D) of genitourinary health	Hospital Anxiety and Depression Scale (HADS): Consists of 14 items, seven for anxiety (HADS-A) and seven for depression (HADS-D), scored on a Likert scale from 0 to 3. Higher scores indicate more anxiety or depression. Clinically significant levels are defined by cutoff scores.	2 years
Secondary	Overall health-related quality of life as assessed by ICIQ-UI short form	The International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) is a validated questionnaire used to assess the impact of urinary incontinence on an individual's health-related quality of life (HRQoL). It specifically focuses on the experience of urinary incontinence, including its frequency, severity, and the degree to which it affects daily activities and emotional well-being.; The total score can be used to classify the severity of urinary incontinence: 0-5: Slight or no impact 6-12: Moderate impact 13-18: Severe impact 19-21: Very severe impact	2 years
Secondary	Overall health-related quality of life as assessed by IPSS	The International Prostate Symptom Score (IPSS) provides a quantitative measure of urinary symptoms, helping clinicians evaluate symptom severity and monitor changes over time.ach question in the IPSS is scored on a Likert scale from 0 to 5, with higher scores indicating greater symptom severity. The total IPSS score is calculated by summing the scores for the individual questions, resulting in a total score ranging from 0 to 35.; Mild: 0-7 Moderate: 8-19 Severe: 20-35	2 years
Secondary	Overall health-related quality of life as assessed by IPSS-QoL	International Prostate Symptom Score-Quality of Life assesses the impact of lower urinary tract symptoms (LUTS) on a patient's quality of life (QoL) specifically related to urinary symptoms associated with benign prostatic hyperplasia (BPH) or prostate enlargement. The IPSS-QoL consists of a single question that asks the patient to rate their perception of how urinary symptoms have affected their quality of life during the past month. The question is scored on a Likert scale from 0 to 6, with the following response options: Delighted (scored as 0) Pleased (scored as 1) Mostly satisfied (scored as 2) Mixed (about equally satisfied and dissatisfied) (scored as 3) Mostly dissatisfied (scored as 4) Unhappy (scored as 5) Terrible (scored as 6)	2 years
Secondary	Overall health-related quality of life as assessed by EQ5D	EuroQol 5-Dimension (EQ-5D) assesses overall health status. Its questionnaire has two components: Descriptive System evaluates health across five dimensions: Mobility, Self-care, Usual activities, Pain/discomfort, and Anxiety/depression, each with three severity levels. This yields 243 possible health states. Visual Analog Scale (VAS) rates overall health from 0 (worst imaginable) to 100 (best imaginable).	2 years
Secondary	The sensitivity, specificity, and accuracy of using portable MRI to detect clinically significant prostate cancer	Detection of clinically significant prostate cancer defined as Gleason grade 3+4 or greater and/or a maximum cancer core length of >/= 4mm.; Detection of clinically significant prostate cancer defined as Gleason grade 4+3 or greater and/or a maximum cancer core length of >/= 6mm.; This outcome will measure the sensitivity, specificity, and accuracy of portable MRI in detecting prostate cancer deemed clinically significant. Sensitivity refers to the proportion of true positive cases detected by the portable MRI, while specificity refers to the proportion of true negative cases correctly identified as negative. Accuracy measures the overall correctness of the portable MRI's detection compared to a standard MRI, or histopathology from biopsy samples.	2 years
Secondary	Concordance Rate of Prostate Cancer Detection between Portable MRI and Standard mpMRI	A matched cohort of mpMRI, portable MRI, targeted and systematic biopsies will be created to estimate concordance of portable MRI compared to mpMRI in the detection of clinically significant cancer. Data from this analysis will allow the development of much larger RCT and screening study.	2 years
Secondary	Patient reported outcome measures (PROMS / EPIC) of genitourinary health	EPIC (urinary, erectile, bowel): Expanded Prostate Cancer Index Composite. The score range is usually from 0 to 100. Higher scores denote better function and quality of life in respective domains.	2 years
Secondary	Patient reported outcome measures (PROMS / EuroQol) of genitourinary health	EuroQol (EQ-5D-5L): EuroQol 5-Dimension 5-Level Scale. Assessing mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses range from no problems to extreme problems. VAS ranges from 0 to 100, reflecting worst to best imaginable health.	2 years